Bacterial vectors containing large inserts of genomic DNA are now the standard substrates for large-scale genomic sequencing. Long overlaps between some clones lead to considerable redundant effort. A method for deleting defined regions from bacterial artificial chromosome (BAC) inserts, using homologous recombination, was applied to minimize the overlap between successive BAC clones. This procedure, called trimming, was carried out in the recA(-) BAC host. We have precisely deleted up to 70 kb of DNA from BACs that were to be sequenced. This method requires minimal prior characterization of the clones: collections of BAC end sequences or STS-based maps will accelerate the process. BAC trimming will be useful in both small and large genome sequencing projects and will be of particular utility for gap closure in finishing phases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1006/geno.1999.6106 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet Diabetes Endocrinol
December 2023
Background: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.
Methods: In the randomised, controlled, open-label RECOVERY trial, several possible treatments are compared with usual care in patients hospitalised with COVID-19.
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.
Mult Scler
July 2023
Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Background: The N-MOmentum trial investigated safety and efficacy of inebilizumab in participants with neuromyelitis optica spectrum disorder (NMOSD).
Objective: Evaluate the attack identification process and adjudication committee (AC) performance in N-MOmentum.
Methods: Adults ( = 230) with NMOSD and Expanded Disability Status Scale score ⩽8 were randomized (3:1) to inebilizumab 300 mg or placebo.
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
EBioMedicine
December 2022
UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Article Synopsis
- Inebilizumab is an anti-CD19 antibody effective for treating neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 autoantibodies, showing significant long-term benefits in reducing disease activity.
- In the N-MOmentum study, treatment led to quick and sustained depletion of B-cells and plasma-cells, with deeper depletion linked to better clinical outcomes, including lower attack rates and fewer new MRI lesions.
- The study concludes that while inebilizumab rapidly depletes B-cells, the extent of this depletion correlates with improved stability and reduced severity of NMOSD symptoms over time.
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
Mult Scler
November 2021
Viela Bio, Gaithersburg, MD, USA.
Background: In the N-MOmentum trial, the risk of an adjudicated neuromyelitis optica spectrum disorder (NMOSD) attack was significantly reduced with inebilizumab compared with placebo.
Objective: To demonstrate the robustness of this finding, using pre-specified sensitivity and subgroup analyses.
Methods: N-MOmentum is a prospective, randomized, placebo-controlled, double-masked trial of inebilizumab, an anti-CD19 monoclonal B-cell-depleting antibody, in patients with NMOSD.
Generating libraries of iTol2-end insertions at BAC ends using loxP and lox511 Tn10 transposons.
BMC Genomics
July 2011
Julius L, Chambers Biomedical/Biotechnology Research Institute & Department of Chemistry, North Carolina Central University, 1801 Fayetteville Street, Durham, NC 27707, USA.
Background: Bacterial Artificial Chromosomes (BACs) have been widely used as transgenes in vertebrate model systems such as mice and zebrafish, for a variety of studies. BAC transgenesis has been a powerful tool to study the function of the genome, and gene regulation by distal cis-regulatory elements. Recently, BAC transgenesis in both mice and zebrafish was further facilitated by development of the transposon-mediated method using the Tol2 element.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!